Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

<h3>Background</h3> We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC). <h3>Methods</h3> In this phase 1b expansion cohort, patients with mACC and...

Full description

Saved in:
Bibliographic Details
Main Authors: Christophe Le Tourneau, Christopher Hoimes, Corrine Zarwan, Deborah Jean Lee Wong, Sebastian Bauer, Rainer Claus, Martin Wermke, Hariharan Subramanian, Anja von Heydebreck, Vijay Kasturi, Vikram K. Chand, James L. Gulley
Format: Artigo
Language:English
Published: 2018
Online Access:https://doi.org/10.1186/s40425-018-0424-9
https://jitc.bmj.com/content/jitc/6/1/111.full.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40425-018-0424-9
https://jitc.bmj.com/content/jitc/6/1/111.full.pdf

Similar Items